Comparative Pharmacology
Head-to-head clinical analysis: ORTHO TRI CYCLEN versus ORTHO NOVUM 10 11 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO TRI CYCLEN versus ORTHO NOVUM 10 11 28.
ORTHO TRI-CYCLEN vs ORTHO-NOVUM 10/11-28
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combined estrogen-progestin oral contraceptive; suppresses gonadotropin release, inhibiting ovulation; increases cervical mucus viscosity and alters endometrial lining.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) via negative feedback inhibition of hypothalamic-pituitary axis, preventing ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.
FDA-approved: Prevention of pregnancyOff-label: Treatment of acne vulgaris, management of menstrual disorders
Prevention of pregnancyTreatment of moderate acne vulgaris (in females ≥15 years who have menarche and desire contraception)Off-label: menstrual cycle regulation, dysmenorrhea, endometriosis-associated pain
One tablet (norgestimate 0.180-0.215-0.250 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo or no tablets.
One tablet daily for 28 days, starting on day 1 of menstrual cycle. Each tablet contains 1 mg norethindrone and 10 mcg ethinyl estradiol for first 10 tablets, then 1 mg norethindrone and 35 mcg ethinyl estradiol for next 11 tablets, followed by 7 placebo tablets.
None Documented
None Documented
Norethindrone: ~8 hours (terminal). Ethinyl estradiol: ~12-15 hours (terminal). Clinical context: Steady-state achieved within 5-7 days; contraceptive efficacy maintained with daily dosing.
Norethindrone: 5-14 hours; Ethinyl estradiol: 8-20 hours. Steady state reached within 5 days. Clinical significance: missed doses may increase pregnancy risk due to rapid decline.
Ethinyl estradiol: primarily metabolized by CYP3A4; norgestimate: rapidly hydrolyzed to norelgestromin (active) then levonorgestrel, metabolized by CYP3A4 and CYP2C9.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes first-pass metabolism with extensive conjugation (glucuronidation and sulfation). Norethindrone: metabolized via reduction, conjugation (glucuronidation), and hydroxylation; also involves CYP3A4 to a lesser extent.
Norethindrone: 60-80% renal (as metabolites), 20-40% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal. Biliary excretion contributes to fecal elimination.
Renal (50-60% as metabolites, <10% unchanged); fecal (30-40%) with biliary elimination of conjugates.
Norethindrone: ~97% bound to albumin and SHBG. Ethinyl estradiol: ~98% bound to albumin.
Norethindrone: 61% bound to albumin and 36% to SHBG; Ethinyl estradiol: 98% bound to albumin.
Norethindrone: 3-4 L/kg (large distribution into tissues, including breast and reproductive tissues). Ethinyl estradiol: 2-3 L/kg (distributes widely).
Norethindrone: 4 L/kg; Ethinyl estradiol: 4-5 L/kg. Indicates extensive tissue distribution.
Norethindrone: ~65% (oral). Ethinyl estradiol: ~40-45% (oral) due to first-pass metabolism.
Oral: Norethindrone ~64%; Ethinyl estradiol ~45% (due to first-pass metabolism).
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe impairment (GFR <30 mL/min); use alternative contraception.
No specific dose adjustment guidelines for renal impairment. Use with caution in patients with renal impairment, as ethinyl estradiol and norethindrone may accumulate. Monitor for fluid retention and hypertension.
Contraindicated in patients with acute hepatitis, cholestatic jaundice of pregnancy or prior OCP use, or severe cirrhosis (Child-Pugh C). Use with caution in Child-Pugh A/B; dose adjustment not defined but consider lower estrogen options.
Contraindicated in patients with severe hepatic disease (Child-Pugh class C) due to potential accumulation and hepatotoxicity. For mild to moderate impairment (Child-Pugh A or B), use with caution; no specific dose adjustment, but monitor liver function tests.
Not indicated in prepubertal children. Postmenarchal adolescents: same dosing as adults. Safety and efficacy not established in children <18 years.
Not indicated for use before menarche. Post-menarche: same dosing as adults (one tablet daily for 28 days). Safety and efficacy in adolescents have not been specifically established; however, use is common off-label.
Not indicated for use after menopause. No specific geriatric dosing; contraindicated in postmenopausal women.
Not indicated for use after menopause. No specific geriatric dosing; however, elderly women should not use combination hormonal contraceptives due to increased risk of thromboembolic events and cardiovascular disease. Use alternative contraception if needed.
Cigarette smoking increases risk of serious cardiovascular events from combined hormonal contraceptive use. Risk increases with age and number of cigarettes smoked, especially in women over 35.
Cigarette smoking increases risk of serious cardiovascular events (myocardial infarction, thromboembolism, stroke) from combination hormonal contraceptive use. Risk increases with age and with smoking intensity (especially >15 cigarettes/day). Women >35 years who smoke should not use this medication.
["Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction)","Hepatic neoplasia (benign/malignant)","Gallbladder disease","Hypertension","Carbohydrate/lipid effects","Hereditary angioedema","Chloasma","Retinal thrombosis","Depression"]
["Thromboembolic disorders (DVT, PE, arterial thrombosis, stroke, MI) – increased risk especially in smokers >35 years, obese, or with hypertension","Cerebrovascular disease","Hepatic disease (including hepatic adenoma or impaired liver function)","Gallbladder disease","Hypertension","Glucose intolerance/diabetes mellitus","Headache (including migraine with or without aura)","Uterine bleeding irregularities","Depression","Possible increased risk of cervical cancer with long-term use"]
["Thrombophlebitis or thromboembolic disorders","Cerebrovascular or coronary artery disease","Known or suspected breast carcinoma","Undiagnosed abnormal genital bleeding","Pregnancy","Active liver disease or benign/malignant liver tumors","Hypersensitivity to any component","Heavy smoking in women over 35"]
["Known or suspected pregnancy","Current or past thromboembolic disorders (DVT, PE, stroke, MI)","Cerebrovascular or coronary artery disease","Known or suspected breast cancer","Estrogen-dependent neoplasia","Hepatic adenomas or carcinomas, or active liver disease (e.g., acute hepatitis)","Undiagnosed abnormal uterine bleeding","Heavy smoking (>15 cigarettes/day) in women ≥35 years"]
Data Pending Review
Data Pending Review
No specific food restrictions. Grapefruit may slightly increase estrogen levels; avoid large amounts. Alcohol consumption may increase hepatic toxicity risk; limit to moderate intake.
No specific food interactions. Grapefruit juice may increase ethinyl estradiol levels, but clinical significance is minimal. Maintain consistent diet. Antacids containing magnesium may reduce absorption if taken within 2 hours. Caution with St. John's Wort, as it may reduce contraceptive efficacy.
Contraindicated in pregnancy. First trimester: associated with cardiovascular defects and limb reduction defects. Second and third trimesters: no increased risk of major malformations, but may cause fetal harm due to hormonal effects; use only if clearly needed.
First trimester: Increased risk of neural tube defects and cardiovascular malformations; second and third trimesters: Risk of fetal growth restriction, preterm birth, and transient metabolic disturbances. Contraindicated during pregnancy (FDA Category X).
Small amounts of ethinyl estradiol and norgestimate pass into breast milk; may reduce milk production and composition. M/P ratio not established. Generally avoided during breastfeeding; alternative contraception recommended.
Excreted in breast milk in small amounts; M/P ratio approximately 0.4. May reduce milk production and quality. Use alternative contraception during breastfeeding.
No dosing adjustments applicable; drug is contraindicated during pregnancy. If used inadvertently, discontinue immediately.
Contraindicated in pregnancy; no dose adjustment applicable. Discontinue if pregnancy occurs.
Category C
Category C
Contains norgestimate 0.180/0.215/0.250 mg and ethinyl estradiol 0.035 mg. Triphasic regimen mimics natural cycle. Monitor for breakthrough bleeding, especially during first 3 cycles. Use with caution in patients with migraine with aura, hypertension, or history of VTE. Effective for acne vulgaris (FDA-approved indication). Counsel that efficacy may be reduced with concurrent rifampin, certain anticonvulsants, and St. John's wort. Consider switching to monophasic pill if persistent breakthrough bleeding after 3 months.
ORTHO-NOVUM 10/11-28 is a biphasic oral contraceptive containing ethinyl estradiol (35 mcg) and norethindrone (0.5 mg/1 mg). The biphasic dosing mimics natural hormonal fluctuations. It is indicated for contraception. Monitor for breakthrough bleeding, especially during the first few cycles. Counsel patients to take at the same time daily and use backup contraception if a dose is missed. Contraindicated in smokers over 35, history of thromboembolism, or migraine with aura.
Take one pill daily at the same time for 21 days, then placebo pills for 7 days.If you miss a pill within 12 hours, take it as soon as remembered. If more than 12 hours late, use backup contraception (e.g., condoms) for 7 days.Do not smoke while taking this medication; smoking increases risk of blood clots and stroke, especially if over 35.Common side effects: spotting between periods, nausea, breast tenderness, headache. These often improve after a few cycles.Seek emergency medical attention for signs of blood clot: leg pain/swelling, sudden chest pain, difficulty breathing, severe headache, vision changes.This medication does not protect against HIV or other sexually transmitted infections.
Take one tablet daily at the same time, following the scheduled order in the pack.Missing pills increases risk of pregnancy; refer to package insert for missed dose instructions.Use backup non-hormonal contraception for 7 days if you miss a dose or start late.Common side effects: nausea, breast tenderness, breakthrough bleeding, and mood changes.Report severe headache, chest pain, leg swelling/pain, or visual disturbances immediately.Smoking while on this pill increases risk of serious cardiovascular events; avoid smoking.Do not take during pregnancy; stop if pregnancy is suspected.